Back to homepage

Tag "rivaroxaban"

Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

Authors: José Luis Hernández MD, PhD, Francisco S Lozano MD, PhD, Vincent Riambau MD, PhD, Manuel Almendro-Delia MD, PhD, Juan Cosín-Sales MD, PhD, Sergi Bellmunt-Montoya MD, PhD, Javier Garcia-Alegria MD, PhD, Xavier Garcia-Moll MD, FESC, FACC, Juan José Gomez-Doblas MD, PhD, José R Gonzalez-Juanatey MD, PhD, Carmen Suarez Fernández MD

In this narrative review, data about how to reduce residual risk through the best antithrombotic
approach among patients with peripheral artery disease, with a particular focus
on the COMPASS trial, are updated in order to provide some
practical recommendations about its use in this population.

More

Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies

Authors: Manuel Anguita MD, Mariano de la Figuera MD, Alejandro I Pérez Cabeza MD, Carmen Suarez Fernández MD

This work analyzed the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain.

More

Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement

Authors: Adam Ioannou, Sofia Metaxa, George Kassianos, Constantinos G Missouris

The aim of this study was to assess whether the recommendations and guidelines for thromboprophylaxis in patients with atrial fibrillation (AF) have been adopted in general practice (GP) in the UK. The authors concluded that one in four patients with non-valvular AF, at risk of a stroke, is not being adequately treated with an oral anticoagulant in primary care and suggest that a review of GP practice databases should be considered to identify patients with non-valvular AF, at risk of a disabling or fatal event, and measures taken to initiate anticoagulant therapy.

More